Intersect ENT, Inc.
(NASDAQ GM: XENT)
Rigrodsky Law, P.A. is investigating Intersect ENT, Inc. (“Intersect”) regarding possible breaches of fiduciary duties and other violations of law related to Intersect’s agreement to be acquired by Medtronic, Inc. Under the terms of the agreement, Intersect’s shareholders will receive $28.25 in cash for each share of Intersect common stock they own.